CA3242755A1 - Deuterated organic compounds and uses thereof - Google Patents

Deuterated organic compounds and uses thereof

Info

Publication number
CA3242755A1
CA3242755A1 CA3242755A CA3242755A CA3242755A1 CA 3242755 A1 CA3242755 A1 CA 3242755A1 CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A1 CA3242755 A1 CA 3242755A1
Authority
CA
Canada
Prior art keywords
deteriorative
organic compounds
compounds
formula
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242755A
Other languages
English (en)
French (fr)
Inventor
Krishna VADODARIA
Kimberly Vanover
Jordi SERRATS
Vikram SUDARSAN
David Garvey
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of CA3242755A1 publication Critical patent/CA3242755A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3242755A 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof Pending CA3242755A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US63/296,137 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US63/314,466 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US63/345,002 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US63/394,565 2022-08-02
US202263384988P 2022-11-25 2022-11-25
US63/384,988 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3242755A1 true CA3242755A1 (en) 2023-07-06

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242755A Pending CA3242755A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Country Status (10)

Country Link
US (1) US12606523B2 (cg-RX-API-DMAC10.html)
EP (1) EP4460292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501411A (cg-RX-API-DMAC10.html)
KR (1) KR20240132477A (cg-RX-API-DMAC10.html)
AU (1) AU2023204433B2 (cg-RX-API-DMAC10.html)
CA (1) CA3242755A1 (cg-RX-API-DMAC10.html)
IL (1) IL313999A (cg-RX-API-DMAC10.html)
MX (1) MX2024008371A (cg-RX-API-DMAC10.html)
TW (1) TW202333671A (cg-RX-API-DMAC10.html)
WO (1) WO2023130119A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (cg-RX-API-DMAC10.html) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
KR100355130B1 (ko) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
JP2025501410A (ja) 2022-01-03 2025-01-17 エングレイル・セラピューティクス・インコーポレイテッド 重水素化有機化合物およびその使用
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof

Also Published As

Publication number Publication date
US20250011280A1 (en) 2025-01-09
KR20240132477A (ko) 2024-09-03
AU2023204433A1 (en) 2024-07-18
WO2023130119A1 (en) 2023-07-06
MX2024008371A (es) 2024-12-06
IL313999A (en) 2024-08-01
AU2023204433B2 (en) 2026-07-30
EP4460292A4 (en) 2025-07-16
JP2025501411A (ja) 2025-01-17
TW202333671A (zh) 2023-09-01
EP4460292A1 (en) 2024-11-13
US12606523B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
BR112022019991A2 (pt) Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
MA32941B1 (fr) Composes organiques
EP3362445A4 (en) OXADIAZOLAMINE DERIVATIVE COMPOUNDS AS HISTONDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREWITH
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
CA3242751A1 (en) Deuterated organic compounds and uses thereof
WO2025010259A3 (en) Deuterated organic compounds and uses thereof
DE602005008065D1 (de) Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
BRPI0612125A2 (pt) compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos
DE602005023755D1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
MX2024008371A (es) Compuestos organicos deuterados y usos de los mismos
EP3694330A4 (en) INDAZOLYL-SPIRO [2.2] PENTANCARBONITRIL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
ATE424384T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
WO2020024017A9 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EP3999045A4 (en) NLRP3 INFLAMMA SUMMER INHIBITOR COMPOUNDS AND COMPOSITIONS AND USES THEREOF
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC REMOVED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240702

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240703

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217